AB | BC | MB | NB | NL | NS | NT | ON | PE | QC | SK | YT

Drug Schedules Notice Board

National Drug Schedules: Final Recommendations on omeprazole tablets and triamcinolone acetonide nasal spray
July 23, 2014

The Interim Recommendations made by the National Drug Scheduling Advisory Committee (NDSAC) on June 17, 2014 were finalized effective July 18, 2014. The final recommendations are as follows:

  • omeprazole or its salts, when sold for the 14-day treatment for frequent heartburn at a daily dose of 20mg, in package sizes of no more than 280mg of omeprazole - be granted Schedule II status once removal from the Prescription Drug List comes into effect.
  •    
  • omeprazole or its salts, when sold for the 14-day treatment for frequent heartburn at a daily dose of 20mg, in package sizes of more than 280mg of omeprazole - will remain in Schedule I once removal from the Prescription Drug List comes into effect.
  • triamcinolone acetonide in an aqueous nasal spray that delivers 55mcg per metered spray for adults and children 12 years of age and older, in package sizes containing no more than 120 metered sprays - be granted Schedule III status - subject to removal from the Prescription Drug List by Health Canada
  • triamcinolone acetonide in an aqueous nasal spray that delivers 55mcg per metered spray for adults and children 12 years of age and older, in package sizes containing more than 120 metered sprays - be granted Schedule II status - subject to removal from the Prescription Drug List by
    Health Canada
           

Final approval of the interim recommendations was made by NAPRA's Executive Committee, in consideration of comments received during the 30-day review period. The National Drug Schedules will be revised accordingly once the affected substances are removed from the Prescription Drug List.




Back